Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses
- 1 March 2009
- journal article
- review article
- Published by Informa UK Limited in Personalized Medicine
- Vol. 6 (2), 193-215
- https://doi.org/10.2217/17410541.6.2.193
Abstract
Trastuzumab is a targeted therapy for human EGF receptor-2 (HER2)-positive breast cancer. The effectiveness and cost–effectiveness of trastuzumab hinges not only on its clinical efficacy in responding patients, but on the ability to accurately identify appropriate therapeutic candidates. We sought to systematically review the cost–effectiveness of trastuzumab with a focus on the impact of the test(s) used for HER2 diagnosis. Our review included 17 economic evaluations or health technology assessments of trastuzumab therapy or HER2 testing. Trastuzumab was considered cost-effective in all early-stage disease studies, while one author concluded that trastuzumab was not cost-effective for metastatic disease. Only two papers considered the joint effects of test accuracy and sequencing with trastuzumab therapy. These demonstrated that trastuzumab cost–effectiveness is sensitive to HER2-test properties.Keywords
This publication has 33 references indexed in Scilit:
- Trastuzumab in the Adjuvant Treatment of Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsThe Oncologist, 2008
- Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysisCMAJ : Canadian Medical Association Journal, 2007
- Do the Large Benefits Justify the Large Costs of Adjuvant Breast Cancer Trastuzumab?Journal of Clinical Oncology, 2007
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- How much will Herceptin really cost?BMJ, 2006
- How much will Herceptin really cost?BMJ, 2006
- Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast CancerNew England Journal of Medicine, 2006
- Patient demand and politics push Herceptin forwardCMAJ : Canadian Medical Association Journal, 2005
- Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncologyAnnals Of Oncology, 2005
- TrastuzumabDrugs, 2002